Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that its CEO, Mel Sorensen, M.D., will speak at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 4:30 p.m. E.T. A live webcast of the presentation will be available on Galera's Investors page, with an archived version accessible for 30 days post-event. Galera focuses on developing innovative therapeutics to enhance radiotherapy for cancer patients, notably its candidates avasopasem manganese and rucosopasem manganese, targeting radiotherapy-induced toxicities and enhancing cancer treatment efficacy.
- None.
- None.
MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:30 p.m. E.T.
A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the Events & Presentations section of the Investors page of Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
William Windham
Solebury Strategic Communications
646-378-2946
wwindham@soleburystrat.com
Media Contact:
Zara Lockshin
Solebury Strategic Communications
646-378-2960
zlockshin@soleburystrat.com
FAQ
What is the date and time of Galera Therapeutics' CEO presentation at the H.C. Wainwright conference?
Where can I watch the live webcast of Galera Therapeutics' presentation?
What are the key products being developed by Galera Therapeutics?
What is the stock symbol for Galera Therapeutics?
How long will the archived version of the webcast be available after the conference?
